Update on the Treatment of Heavily Pretreated, Relapsed Refractory Multiple Myeloma
Abstract:
Multiple myeloma is the second most common hematologic malignancy in the United States, accounting for approximately 17% of all blood cancers. It is characterized by unchecked production of monoclonal plasma cells in the bone marrow, leading to high levels of dysfunctional (monoclonal) immunoglobulins in the blood and urine. According to recent estimates, more than 32,000 individuals will be diagnosed with multiple myeloma in the United States in 2020. Therapeutic advances over the last decade have led to prolonged survival, but the prognosis remains poor and the disease is incurable.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Psychosis: Goals of Pharmacotherapy
Tumor Immunotherapy


